ISRCTN94245249 https://doi.org/10.1186/ISRCTN94245249

Pilot study on the effects of oral immuno-nutrition on the quality of life in patients receiving palliative treatment for oesophageal and proximal gastric cancer.

Submission date 30/09/2005	**Recruitment status** No longer recruiting	[_] Prospectively registered [_] Protocol
Registration date 30/09/2005	**Overall study status** Completed	[_] Statistical analysis plan [_] Results
Last Edited 05/03/2020	**Condition category** Cancer	[_] Individual participant data [_] Record updated in last year

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Mr Martin White

Contact details
North Cumbria Acute Hospitals NHS Trust
Cumberland Infirmary
Carlisle
United Kingdom
CA2 7HY

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers
N0055143763

Study information

Scientific Title
Pilot study on the effects of oral immuno-nutrition on the quality of life in patients receiving palliative treatment for oesophageal and proximal gastric cancer.

Study objectives
Does EPA supplementation affect patients' quality of life and survival with known esophageal and proximal gastric cancer who are receiving non-curative treatments?

Ethics approval required
Old ethics approval format

Ethics approval(s)
Not provided at time of registration

Study design
Randomised controlled trial

Primary study design
Interventional

Secondary study design
Randomised controlled trial

Study setting(s)
Not specified

Study type(s)
Quality of life

Participant information sheet
Not available in web format, please use the contact details below to request a patient information sheet

Health condition(s) or problem(s) studied
Cancer: Gastrointestinal

Interventions
Patients, after obtaining informed consent, are randomly assigned one of the nutritional supplements, both of similar calorific value but one contains EPA.

Intervention Type
Other

Phase
Not Specified

Primary outcome measure

Measurements of QoL, weight etc. are made at monthly interval, follow-up until death.

Secondary outcome measures
Not provided at time of registration

Overall study start date
01/06/2002

Completion date
30/06/2004

Eligibility

Key inclusion criteria
Patients with histologically diagnosed oesophageal or proximal gastric cancer that are not receiving curative treatment.

Participant type(s)
Patient

Age group
Not Specified

Sex
Not Specified

Target number of participants
Not provided at time of registration

Key exclusion criteria
Not provided at time of registration

Date of first enrolment
01/06/2002

Date of final enrolment
30/06/2004

Locations

Countries of recruitment
England

United Kingdom

Study participating centre
North Cumbria Acute Hospitals NHS Trust
Carlisle

United Kingdom
CA2 7HY

Sponsor information

Organisation
Department of Health

Sponsor details
Richmond House
79 Whitehall
London
United Kingdom
SW1A 2NL
+44 (0)20 7307 2622
dhmail@doh.gsi.org.uk

Sponsor type
Government

Website
http://www.dh.gov.uk/Home/fs/en

Funder(s)

Funder type
Government

Funder Name
North Cumbria Acute Hospitals NHS Trust (UK)

Results and Publications

Publication and dissemination plan
Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration